Biopharmx Corp (NYSEAMERICAN:BPMX) was the recipient of a significant decline in short interest in the month of January. As of January 12th, there was short interest totalling 6,056,385 shares, a decline of 4.2% from the December 29th total of 6,319,421 shares. Based on an average trading volume of 5,768,971 shares, the days-to-cover ratio is currently 1.0 days. Currently, 5.7% of the shares of the company are short sold.
Shares of Biopharmx (BPMX) opened at $0.13 on Thursday. The stock has a market cap of $16.18, a P/E ratio of -0.48 and a beta of 1.33. Biopharmx has a 1 year low of $0.10 and a 1 year high of $0.90.
Biopharmx (NYSEAMERICAN:BPMX) last released its quarterly earnings data on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05).
In other Biopharmx news, Director Stephen Morlock acquired 330,000 shares of the company’s stock in a transaction that occurred on Friday, November 24th. The shares were bought at an average price of $0.15 per share, with a total value of $49,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The disclosure for this sale can be found here.
Biopharmx Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.